5F-PB-22 (quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate) is a synthetic cannabinoid receptor agonist in the indolecarboxylate (ester) class. It is the 5-fluoro derivative of PB-22, characterized by a quinoline head group connected via an ester linkage to an indole core with a fluorinated pentyl chain. The ester linkage is pharmacologically significant: it is hydrolyzable by tissue esterases, potentially releasing active fragments in vivo and contributing to both the pharmacological activity and metabolic profile distinct from amide-linked synthetic cannabinoids.
5F-PB-22 is a potent full agonist at CB1 and CB2 receptors. Like other fluorinated synthetic cannabinoids, it was developed in part to evade regulatory scheduling of its non-fluorinated parent. It has been associated with multiple serious adverse events, deaths, and mass poisoning incidents. The quinoline head group and ester linkage distinguish its chemistry from the indazole and adamantyl compounds, but the toxicological profile — dominated by full CB1 agonism — is similar.
Safety at a Glance
High Risk- No Safe Use Pattern
- Emergency Indicators
- Toxicity: Documented Severe Toxicity 5F-PB-22 has been linked to confirmed fatalities and severe adverse events. Emergency and ...
- Overdose risk: overdose will cause physical discomfort including heart palpitations, vertigo and sedation at muc...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
smoked
Duration
oral
Total: 2 hrs – 3 hrssmoked
Total: 1 hrs – 3 hrsHow It Feels
5F-PB-22 wraps itself around consciousness like a warm, synthetic fog. The onset after inhalation is rapid -- within one to five minutes -- and it arrives with a heaviness that is immediately more sedating than most natural cannabis strains. A warmth blooms in the chest and radiates outward, carrying with it a thick, cottony drowsiness that settles over the mind like a heavy curtain. The eyes grow heavy. The body sinks.
At the peak, the sedation is the dominant feature. The body becomes profoundly heavy, each limb weighted with a gravitational pull that makes movement feel like an enormous effort. The mind slows to a crawl, thoughts arriving with the sluggish pace of honey dripping from a spoon. There is a warmth to the experience that is genuinely pleasant -- a full-body glow that resembles an amplified version of the most sedating indica strains. But beneath the warmth, there is a synthetic edge that cannot quite be ignored: a faint chemical taste in the mouth, a slight pressure behind the eyes, a quality to the intoxication that feels manufactured rather than grown.
Time distortion is significant. Minutes stretch into vast, empty intervals where very little happens but everything feels consequential. The emotional tone is flat rather than euphoric -- there is neither particular joy nor particular sadness, just a vast, warm indifference that makes the world's demands feel irrelevant. Short-term memory is severely compromised, conversations and thoughts evaporating almost as quickly as they form. You may find yourself staring at a single point for extended periods, not lost in thought exactly but lost in the absence of thought, consciousness reduced to a warm, empty hum.
The body responds with heavy eyelids, dry mouth, and a hunger that can surface with surprising intensity despite the general immobility. The heart rate may elevate, though the sedation often masks the awareness of it. Coordination is significantly impaired -- walking feels uncertain, handling objects becomes clumsy, and the disconnect between intention and execution widens into a noticeable gap.
The duration of primary effects is one to two hours, though the residual sedation can persist for considerably longer, leaving a drowsy, foggy aftermath that gradually clears over the course of several hours. The comedown is smooth relative to some synthetic cannabinoids, lacking the sharp anxiety or headache that characterize harsher compounds. What remains is a heavy-limbed tiredness, a cotton mouth, and a vague hunger that is best addressed before sleep overtakes the will to eat.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(17)
- Appetite enhancement— A distinct increase in hunger and desire for food, often accompanied by enhanced enjoyment of taste ...
- Decreased blood pressure— Decreased blood pressure (hypotension) is a drop in arterial blood pressure below normal levels, com...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Dizziness— A sensation of spinning, swaying, or lightheadedness that impairs balance and spatial orientation, o...
- Dry mouth— A persistent, uncomfortable reduction in saliva production causing the mouth and throat to feel parc...
- Headache— A painful sensation of pressure, throbbing, or aching in the head that can range from a dull backgro...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Motor control loss— A distinct decrease in the ability to control one's physical body with precision, balance, and coord...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Pain relief— A suppression of negative physical sensations such as aches and pains, ranging from dulled awareness...
- Perception of bodily heaviness— Perception of bodily heaviness is the subjective feeling that one's body has become dramatically hea...
- Perception of bodily lightness— Perception of bodily lightness is the subjective feeling that one's body has become dramatically lig...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Vasodilation— Vasodilation is the relaxation and widening of blood vessels, leading to increased blood flow, reduc...
Cognitive & Perceptual Effects
Visual(2)
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
Cognitive(11)
- Analysis suppression— Analysis suppression is a cognitive impairment in which the capacity for logical reasoning, critical...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Dream suppression— Dream suppression is a decrease in the intensity, frequency, and recollection of dreams — ranging fr...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Mindfulness— Mindfulness in the substance context refers to a state of heightened present-moment awareness in whi...
- Paranoia— Irrational suspicion and belief that others are watching, plotting against, or intending harm toward...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Thought connectivity— A state in which disparate thoughts, concepts, and ideas become fluidly and spontaneously interconne...
- Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
Pharmacology
Mechanism of Action
5F-PB-22 acts as a potent full agonist at both CB1 andCB2 cannabinoid receptors. The quinoline head group provides high affinity for the CB1 orthosteric binding site, and full agonism produces the maximum possible physiological response.
Ester Linkage and Metabolism
The carboxylate ester linkage connecting the quinoline and indole components is susceptible to hydrolysis by tissue carboxylesterases. This creates a metabolic pathway distinct from amide-linked analogs (AB-FUBINACA, AKB48) and may generate active or toxic metabolites including the liberated quinoline fragment. The metabolic fate of 5F-PB-22 and its contribution to observed toxicity have been studied in forensic toxicology contexts.
Fluorination Effects
As with 5F-AKB48, the 5-fluoropentyl chain increases metabolic stability relative to the unfluorinated parent (PB-22), potentially prolonging tissue exposure.
Detection Methods
Standard Drug Panel Inclusion
5F-PB-22 is a synthetic cannabinoid receptor agonist that is not detected on standard 5-panel drug screens. Standard THC immunoassays target 11-nor-9-carboxy-THC (THC-COOH), the primary metabolite of delta-9-THC, and do not cross-react with synthetic cannabinoids. Some expanded drug panels (12-panel or custom panels) include a synthetic cannabinoid channel, but coverage of specific compounds varies widely between manufacturers.
Urine Detection
5F-PB-22 and its metabolites can be detected in urine for approximately 2 to 5 days after a single use, though chronic heavy use can extend this window to 7 or more days. Synthetic cannabinoids undergo extensive hepatic metabolism, primarily via hydroxylation and carboxylation, producing metabolites that are excreted in urine as glucuronide conjugates. The specific metabolite profile varies by compound and is a key factor in whether a given immunoassay can detect 5F-PB-22.
Blood and Saliva Detection
Blood concentrations of 5F-PB-22 decline rapidly after use, with a detection window of approximately 12 to 48 hours for the parent compound. Metabolites may persist longer. Oral fluid testing can detect parent compound and early metabolites for approximately 24 to 48 hours, and some roadside testing devices include synthetic cannabinoid panels.
Hair Follicle Detection
Hair follicle analysis can detect synthetic cannabinoids for up to 90 days. However, incorporation rates and detectability vary by compound. Some laboratories offer expanded hair panels that include common synthetic cannabinoids such as JWH-018 and AB-FUBINACA metabolites, but coverage of newer compounds including 5F-PB-22 may be limited.
Confirmatory Testing
LC-MS/MS is the preferred confirmatory method for synthetic cannabinoids. The structural diversity and rapid evolution of this substance class means that reference standards must be available for the specific compound under investigation. GC-MS can also be used but LC-MS/MS offers superior sensitivity and specificity for the typically low concentrations encountered. Both parent compound and key metabolites should be targeted.
Reagent Testing
Standard reagent tests (Marquis, Mecke, Mandelin) are generally uninformative for synthetic cannabinoids, as these compounds are typically applied to herbal material at very low concentrations and produce no characteristic color reactions. Visual inspection and reagent testing cannot distinguish treated herbal material from untreated plant matter. Immunoassay-based test strips specific to synthetic cannabinoids are available from some harm reduction suppliers and represent a more practical point-of-use screening option.
Interactions
| Substance | Status | Note |
|---|---|---|
| 1,3-Butanediol | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| 25E-NBOH | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| 2C-T | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| 2C-T-2 | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| 2C-T-21 | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| 25x-NBOMe | Uncertain | — |
| 2C-T-x | Uncertain | — |
| 2C-x | Uncertain | — |
| Cocaine | Uncertain | — |
| DMT | Uncertain | — |
History
Development and Market Entry
5F-PB-22 was developed as a fluorinated analog of PB-22, which itself was developed as a quinoline-based structural alternative to earlier synthetic cannabinoids. It entered the market around 2013, appearing in herbal incense and "spice" products primarily in North America, Europe, and Japan.
Scheduling
5F-PB-22 was emergency-scheduled by the US DEA as a Schedule I compound in 2014, and has been controlled in the UK, EU member states, and Japan. The ester-linked quinoline scaffold represents a distinct chemical class from earlier indazole compounds, contributing to initial gaps in regulatory coverage.
Forensic Significance
5F-PB-22 has appeared in multiple forensic toxicology reports associated with deaths, and is included in standard synthetic cannabinoid screening panels in forensic laboratories. Its detection in postmortem samples has contributed to the characterization of the lethal toxicity profile of the ester-class synthetic cannabinoids.
Harm Reduction
No Safe Use Pattern
The lack of a pharmacological ceiling, dose uncertainty from product contamination, and documented mass fatality events collectively mean that no dosing pattern eliminates the risk of life-threatening harm with 5F-PB-22.
Emergency Indicators
Seek immediate emergency care for: seizures, chest pain, breathing difficulty, loss of consciousness, severe psychiatric symptoms, flank pain suggesting renal involvement, or arrhythmia.
Basic Precautions If Use Continues
- Never use alone
- Minimum exposure — single small inhalation, 20-minute wait
- No mixing with CNS depressants, stimulants, or other substances
- Know the location of the nearest emergency room
Toxicity & Safety
Documented Severe Toxicity
5F-PB-22 has been linked to confirmed fatalities and severe adverse events. Emergency and forensic reports document cardiovascular failure, seizures, renal failure, and acute psychotic episodes. Mass poisoning events involving products containing 5F-PB-22 have been reported in public health literature.
Cardiovascular and Renal Events
The full agonist profile at cardiac CB1 receptors, combined with the altered metabolic profile of the ester-linked compound, contributes to the cardiovascular toxicity profile. Renal failure cases — which are not associated with THC and appear to be a specific synthetic cannabinoid toxicity — have been attributed to 5F-PB-22 in toxicological analyses.
Psychiatric Toxicity
Acute psychosis requiring psychiatric hospitalization has been attributed to 5F-PB-22 use in multiple case reports. The quinoline fragment generated by ester hydrolysis may contribute pharmacological effects distinct from CB1 agonism.
Addiction Potential
moderately addictive with a high potential for abuse
Overdose Information
overdose will cause physical discomfort including heart palpitations, vertigo and sedation at much lower than dangerous doses, usually causing the user to suffer large amounts of anxiety or to fall asleep.
There have been many hospital reports involving 5F-PB-22, as well as cases of post-mortem analysis involving 5F-PB-22. Five deaths have been associated with the use of 5F-PB-22 in the United States., particularly in vulnerable individuals with risk factors for psychotic illnesses (like a past or family history of schizophrenia).
Germany: 5F-PB-22 is controlled under Anlage II BtMG (Narcotics Act, Schedule II) as of December 13, 2014. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Latvia: 5F-PB-22 is a Schedule I controlled substance.
Switzerland: 5F-PB-22 is a controlled substance specifically named under Verzeichnis D.
United Kingdom: 5F-PB-22 is a Class B controlled substance under the third-generation synthetic cannabinoids generic definition, which came into effect on December 14, 2016 and is illegal to possess, produce, supply, or import.
United States: In January 2014, 5F-PB-22 was designated as a Schedule I controlled substance in the United States.
Responsible use
THJ-018
Synthetic cannabinoid
5F-PB-22 (Wikipedia)
5F-PB-22 (Isomer Design)
Tolerance
| Full | develops with prolonged and repeated use |
| Half | 3 - 7 days |
| Zero | 1 - 2 weeks |
Cross-tolerances
Legal Status
5F-PB-22 was developed to bypass drug prohibition laws which have banned the possession and sale of many synthetic cannabinoids. As such, it remains legal in many parts of the world.
China: As of October 2015 5F-PB-22 is a controlled substance in China.
Germany: 5F-PB-22 is controlled under Anlage II BtMG (Narcotics Act, Schedule II) as of December 13, 2014. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Latvia: 5F-PB-22 is a Schedule I controlled substance.
Switzerland: 5F-PB-22 is a controlled substance specifically named under Verzeichnis D.
United Kingdom: 5F-PB-22 is a Class B controlled substance under the third-generation synthetic cannabinoids generic definition, which came into effect on December 14, 2016 and is illegal to possess, produce, supply, or import.
United States: In January 2014, 5F-PB-22 was designated as a Schedule I controlled substance in the United States.
Responsible use
THJ-018
Synthetic cannabinoid
5F-PB-22 (Wikipedia)
5F-PB-22 (Isomer Design)
Tips (4)
Never mix 5F-PB-22 with other substances, especially depressants or stimulants. Synthetic cannabinoids have unpredictable pharmacology and interactions can be severe, including cardiac events and seizures.
Dose 5F-PB-22 extremely conservatively. Synthetic cannabinoids are active at much lower doses than THC and potency varies enormously between batches. A dose that was mild from one batch could be dangerously strong from another.
Synthetic cannabinoids like 5F-PB-22 are far more dangerous than natural cannabis. They are full agonists at CB1 receptors, producing much stronger effects with a higher risk of seizures, psychosis, and organ damage.
Consider whether the risk of 5F-PB-22 is worth it compared to natural cannabis where available. Synthetic cannabinoids were created to evade drug tests and laws, not because they are better or safer than cannabis.
See Also
References (3)
- PubChem: 5F-PB-22
PubChem compound page for 5F-PB-22 (CID: 72710774)
pubchem - 5F-PB-22 - TripSit Factsheet
TripSit factsheet for 5F-PB-22
tripsit - 5F-PB-22 - Wikipedia
Wikipedia article on 5F-PB-22
wikipedia